Susquehanna International Group, LLP Viracta Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$1.26 - $4.38 $71,568 - $248,784	-56,800 Reduced 78.78%	15,300 $22,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $64,740 - $110,955	-19,500 Reduced 21.29%	72,100 $308,000
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $16,269 - $43,500	8,700 Added 10.49%	91,600 $355,000
Q1 2022 May 16, 2022	BUY	$2.23 - $4.76 $135,138 - $288,456	60,600 Added 271.75%	82,900 $395,000
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $15,165 - $35,595	-4,500 Reduced 16.79%	22,300 $81,000
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $112,112 - $179,179	-14,300 Reduced 34.79%	26,800 $215,000
Q2 2021 Aug 11, 2021	BUY	$7.55 - $12.95 $10,570 - $18,130	1,400 Added 3.53%	41,100 $466,000
Q1 2021 May 17, 2021	BUY	$7.58 - $18.67 $300,926 - $741,199	39,700 New	39,700 $367,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.